Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (529)	2/10/2002 5:34:07 PM
From: scaram(o)uche	Respond to of 550

SU6668 was the molecule that held my interest. I haven't tried to follow it beyond entry to phase I testing, as I sort of lost "investment interest" with respect to anti-angio. Anybody heard of any SU6668 update? Toxic as heck??

To: tnsaf who wrote (529)	2/26/2002 12:58:16 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 550

from a pointer, today's BioCentury article "Pharmacogenetics might have helped"............ Science 2002 Feb 22;295(5559):1526-8 Effect of p53 status on tumor response to antiangiogenic therapy. Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Sunnybrook and Women's College Health Sciences Centre, Molecular and Cellular Biology Research, Room S-218, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. The p53 tumor suppressor gene is inactivated in the majority of human cancers. Tumor cells deficient in p53 display a diminished rate of apoptosis under hypoxic conditions, a circumstance that might reduce their reliance on vascular supply, and hence their responsiveness to antiangiogenic therapy. Here, we report that mice bearing tumors derived from p53(-/-) HCT116 human colorectal cancer cells were less responsive to antiangiogenic combination therapy than mice bearing isogenic p53(+/+) tumors. Thus, although antiangiogenic therapy targets genetically stable endothelial cells in the tumor vasculature, genetic alterations that decrease the vascular dependence of tumor cells can influence the therapeutic response of tumors to this therapy.